Cognition Therapeutics (NASDAQ: CGTX) has announced that James Edward Galvin, MD, MPH, will present results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral presentation at the Alzheimer’s Association International Conference (AAIC) on July 29, 2025, at 8:00 am ET.
Dr. Galvin is director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and was the SHIMMER study director.
In a statement, Dr. Galvin commented, “The results of the Phase 2 SHIMMER study give hope to the millions of people living with DLB and their healthcare teams, who struggle to treat this complex disease. My colleagues and I believe that there is great potential in a once-daily oral medication that slows disease progress while simultaneously reducing the severity and frequency of some of the most troublesome symptoms of DLB.”
Anthony Caggiano, MD, PhD, CMO and head of R&D at Cognition, added, “Zervimesine’s broad neuroprotective mechanism is illustrated by the favorable results observed in the Phase 2 SHIMMER study in DLB. In the SHIMMER study, zervimesine treatment slowed the progression of DLB’s diverse symptomology, with a meaningful impact on neuropsychiatric, motor, functional, and cognitive measures. Results from the Phase 2 SHINE study in people with Alzheimer’s disease add further evidence to zervimesine’s neuroprotective properties. We look forward to presenting results from both studies at AAIC.”
